Meeting
2011 ASCO Annual Meeting
H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC).
Authors
T. Rampias
BRFAA, New Haven, CT
T. Rampias , A. Giagini , K. Florou , P. Gouveris , E. Vaja , N. Haralambakis , P. Katsaounis , D. G. Pectasides , T. Economopoulos , A. Psyrri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5513)
Abstract #
5513
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition.
First Author: Katharina Endhardt
Poster
2014 ASCO Annual Meeting
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
First Author: Eiji Shinozaki
Poster
2013 ASCO Annual Meeting
Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C.
First Author: Barbara Burtness
Poster
2013 ASCO Annual Meeting
Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
First Author: Henry Li